# Comparative evaluation of molecular technologies for the identification of prevalent non-tuberculous mycobacteria in pulmonary infections: a systematic review and meta-analysis

**Authors:** Xiang Chen, Jiawen Sun, Xibin Chen, Yanshan You, Leonardo Antonio Sechi, Paola Molicotti

PMC · DOI: 10.1080/07853890.2026.2626123 · 2026-02-10

## TL;DR

This study evaluates molecular methods for identifying non-tuberculous mycobacteria in lung infections and finds they are highly accurate, though performance varies with sample type.

## Contribution

The study provides a systematic review and meta-analysis comparing molecular technologies for NTM identification and reports global antibiotic resistance patterns.

## Key findings

- Molecular technologies like MALDI-TOF MS, PCR, and sequencing show high sensitivity (>0.92) for NTM species identification.
- Sample type significantly affects the performance of MALDI-TOF MS in NTM identification.
- Antibiotic resistance rates vary widely, with high Ethambutol resistance in M. avium and Imipenem resistance in rapidly growing mycobacteria.

## Abstract

The increasing prevalence of non-tuberculous mycobacteria pulmonary disease (NTM PD) is a burden to public health. Successful management of NTM PD critically depends on accurate species identification and reliable drug susceptibility testing to guide appropriate antibiotic therapy. Emerging molecular technologies offer rapid diagnostic solutions compared to conventional methods, but their performance varies. This study aims to provide a comprehensive evaluation of current molecular techniques for NTM identification and to present a global antibiotic resistance profile.

A systematic literature search was conducted in PubMed and Web of Science for studies published between 2005 and 2024. Studies applying molecular methods for NTM identification and resistance detection in humans were included. Data on study characteristics, diagnostic methods, sample types, sample sizes, identification sensitivity, and drug susceptibility results were extracted. Meta-analysis was performed using R with the meta4diag package. The quality of included studies was assessed using the QUADAS-2 tool.

The analysis included 49 studies on NTM identification and 33 studies on antibiotic resistance. For species identification, all evaluated molecular technologies (MALDI-TOF MS, PCR-based methods, Sequencing, DNA chip, and DNA strip) demonstrated high pooled sensitivities (>0.92). Subgroup analysis revealed that sample type significantly affected performance for MALDI-TOF MS. Preliminary analysis of antibiotic resistance rates revealed varying patterns. For slowly growing mycobacteria, a significantly high Ethambutol resistance rate was observed in M. avium (69.20%). Among rapidly growing mycobacteria, resistance to Imipenem was notable (54.22%), and Clarithromycin resistance varied significantly within the Mycobacterium abscessus complex.

Emerging molecular technologies have revolutionized the methodology for NTM identification with excellent performance. However, their performance can be influenced by sample type, particularly for MALDI-TOF MS. The alarming and heterogeneous antibiotic resistance patterns also highlight the critical need for rapid and accurate species identification and drug susceptibility testing to inform effective therapeutic strategies.
Key messagesMolecular technologies demonstrate high accuracy for NTM identification.Antibiotic resistance is a serious concern with variations among NTM species and subspecies.Rapid and accurate species identification and drug susceptibility testing are crucial for guiding effective clinical management of NTM PD.

Molecular technologies demonstrate high accuracy for NTM identification.

Antibiotic resistance is a serious concern with variations among NTM species and subspecies.

Rapid and accurate species identification and drug susceptibility testing are crucial for guiding effective clinical management of NTM PD.

## Linked entities

- **Chemicals:** Ethambutol (PubChem CID 14052), Imipenem (PubChem CID 104838), Clarithromycin (PubChem CID 84029)
- **Species:** Mycobacterium avium (taxon 1764)

## Full-text entities

- **Diseases:** pulmonary infections (MESH:D012141), NTM PD (MESH:D008171)
- **Chemicals:** Ethambutol (MESH:D004977), Clarithromycin (MESH:D017291), Imipenem (MESH:D015378)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mycobacteriales (order) [taxon 85007], Mycobacterium avium (species) [taxon 1764]

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12895907/full.md

---
Source: https://tomesphere.com/paper/PMC12895907